Loading...
XASXCYC
Market cap106mUSD
Dec 27, Last price  
1.54AUD
1D
1.99%
1Q
4.76%
Jan 2017
70.76%
IPO
-28.70%
Name

Cyclopharm Ltd

Chart & Performance

D1W1MN
XASX:CYC chart
P/E
—
P/S
6.31
EPS
—
Div Yield, %
0.52%
Shrs. gr., 5y
6.39%
Rev. gr., 5y
15.15%
Revenues
27m
+16.89%
11,128,22410,888,26913,112,4209,464,60510,314,50610,743,82411,882,13412,046,79712,582,51914,385,50713,188,75213,404,22214,078,80114,676,15717,704,57423,218,79727,139,561
Net income
-5m
L-28.90%
1,131,2391,757,0622,044,490450,106-956,220-1,044,127-779,9544,065,5634,793,047891,368-1,524,571-35,456-2,912,440-6,043,636-5,040,166-6,611,515-4,700,806
CFO
-7m
L+8.00%
146,0991,486,0290-90,960563,627369,285706,7064,468,7804,154,834654,794-682,121-1,107,335-489,340-8,934,868-1,629,410-6,664,485-7,197,632
Dividend
Sep 01, 20230.005 AUD/sh
Earnings
Feb 26, 2025

Profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
URL
https://www.cyclopharm.com/
IPO date
Jan 18, 2007
Employees
63
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
27,140
16.89%
23,219
31.15%
17,705
20.63%
Cost of revenue
42,380
34,608
27,977
Unusual Expense (Income)
NOPBT
(15,240)
(11,389)
(10,272)
NOPBT Margin
Operating Taxes
511
(1,054)
(1,598)
Tax Rate
NOPAT
(15,751)
(10,335)
(8,674)
Net income
(4,701)
-28.90%
(6,612)
31.18%
(5,040)
-16.60%
Dividends
(885)
(883)
(881)
Dividend yield
0.49%
0.82%
0.60%
Proceeds from repurchase of equity
29,684
BB yield
-20.21%
Debt
Debt current
214
210
178
Long-term debt
8,240
8,243
8,663
Deferred revenue
902
902
897
Other long-term liabilities
71
(1)
Net debt
(3,272)
(22,225)
(30,422)
Cash flow
Cash from operating activities
(7,198)
(6,664)
(1,629)
CAPEX
(237)
(1,548)
(1,161)
Cash from investing activities
(508)
(1,548)
(1,161)
Cash from financing activities
(1,019)
(726)
30,172
FCF
(19,542)
(12,774)
(7,300)
Balance
Cash
11,726
20,296
29,249
Long term investments
1
10,382
10,014
Excess cash
10,369
29,517
38,378
Stockholders' equity
32,259
36,537
43,068
Invested Capital
27,090
12,163
9,999
ROIC
ROCE
EV
Common stock shares outstanding
92,664
92,179
89,571
Price
1.93
64.96%
1.17
-28.66%
1.64
-34.40%
Market cap
178,841
65.82%
107,849
-26.58%
146,896
-23.28%
EV
175,569
85,624
116,474
EBITDA
(14,301)
(10,457)
(9,514)
EV/EBITDA
Interest
216
266
89
Interest/NOPBT